AbbVie has struck a new drug pricing agreement with the White House that aligns with the administration’s most-favored-nation pricing initiative. Under the deal, the company will lower prices on select medicines for Medicaid and expand direct-to-patient offerings through the TrumpRx platform, while committing to $100 billion in U.S. research, development and capital investment over the next decade. In return, AbbVie earns exemptions from tariffs and future pricing mandates — a significant regulatory reprieve amid broader industry negotiations on drug costs.
Click here to read the entire article.
